The role of B7-1 in proteinuria of glomerular origin

[1]  D. Gipson,et al.  Randomized Clinical Trial Design to Assess Abatacept in Resistant Nephrotic Syndrome , 2017, Kidney international reports.

[2]  P. Mundel.  Podocytes and the quest for precision medicines for kidney diseases , 2017, Pflügers Archiv - European Journal of Physiology.

[3]  Á. Valverde,et al.  Inhibition of T-cell activation by the CTLA4-Fc Abatacept is sufficient to ameliorate proteinuric kidney disease. , 2017, American journal of physiology. Renal physiology.

[4]  D. Chae,et al.  Tubular B7-1 expression parallels proteinuria levels, but not clinical outcomes in adult minimal change disease patients , 2017, Scientific Reports.

[5]  B. Smeets,et al.  Minimal change disease and idiopathic FSGS: manifestations of the same disease , 2016, Nature Reviews Nephrology.

[6]  P. Mundel.  Podocyte-Targeted Treatment for Proteinuric Kidney Disease. , 2016, Seminars in nephrology.

[7]  G. Canaud,et al.  The costimulatory receptor B7-1 is not induced in injured podocytes , 2016, Kidney international.

[8]  G. Canaud,et al.  B7-1 Blockade Does Not Improve Post-Transplant Nephrotic Syndrome Caused by Recurrent FSGS. , 2016, Journal of the American Society of Nephrology : JASN.

[9]  G. Remuzzi,et al.  Another Piece of the Puzzle of Podocyte B7-1 Expression: Lupus Nephritis , 2016, Nephron.

[10]  K. Coppieters,et al.  Abatacept Treatment Does Not Preserve Renal Function in the Streptozocin-Induced Model of Diabetic Nephropathy , 2016, PloS one.

[11]  G. Remuzzi,et al.  B7-1 Is Not Induced in Podocytes of Human and Experimental Diabetic Nephropathy. , 2016, Journal of the American Society of Nephrology : JASN.

[12]  D. Salant.  Podocyte Expression of B7-1/CD80: Is it a Reliable Biomarker for the Treatment of Proteinuric Kidney Diseases with Abatacept? , 2016, Journal of the American Society of Nephrology : JASN.

[13]  G. Remuzzi,et al.  Any value of podocyte B7-1 as a biomarker in human MCD and FSGS? , 2016, American journal of physiology. Renal physiology.

[14]  G. Appel.  Therapy: New data do not support use of abatacept in diabetic nephropathy , 2015, Nature Reviews Nephrology.

[15]  L. Rostaing,et al.  Belatacept in recurrent focal segmental glomerulosclerosis after kidney transplantation , 2015, Transplant international : official journal of the European Society for Organ Transplantation.

[16]  P. Mundel,et al.  Developing therapeutic ‘arrows’ with the precision of William Tell: the time has come for targeted therapies in kidney disease , 2015, Current opinion in nephrology and hypertension.

[17]  Y. Qiu,et al.  Reducing progression of experimental lupus nephritis via inhibition of the B7/CD28 signaling pathway , 2015, Molecular medicine reports.

[18]  Richard J. Johnson,et al.  Case series: CTLA4-IgG1 therapy in minimal change disease and focal segmental glomerulosclerosis , 2015, Pediatric Nephrology.

[19]  Zhi Chen,et al.  Urinary CD80 levels as a diagnostic biomarker of minimal change disease , 2015, Pediatric Nephrology.

[20]  P. Walker,et al.  B7-1 immunostaining in proteinuric kidney disease. , 2014, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[21]  B. Rovin,et al.  Treatment of Lupus Nephritis With Abatacept: The Abatacept and Cyclophosphamide Combination Efficacy and Safety Study , 2014, Arthritis & rheumatology.

[22]  Michael J. Randles,et al.  The Importance of Podocyte Adhesion for a Healthy Glomerulus , 2014, Front. Endocrinol..

[23]  D. Sansom,et al.  Understanding the CD28/CTLA‐4 (CD152) Pathway and Its Implications for Costimulatory Blockade , 2014, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[24]  M. Rastaldi,et al.  Role of podocyte B7-1 in diabetic nephropathy. , 2014, Journal of the American Society of Nephrology : JASN.

[25]  J. Reiser,et al.  Abatacept in B7-1-positive proteinuric kidney disease. , 2014, The New England journal of medicine.

[26]  J. Reiser,et al.  Proteinuria: Abate or applaud abatacept in proteinuric kidney disease? , 2014, Nature Reviews Nephrology.

[27]  F. Houssiau,et al.  Efficacy and Safety of Abatacept in Lupus Nephritis: A Twelve‐Month, Randomized, Double‐Blind Study , 2014, Arthritis & rheumatology.

[28]  M. Arnaout,et al.  Abatacept in B7-1-positive proteinuric kidney disease. , 2013, The New England journal of medicine.

[29]  Chun Zhang,et al.  Actin-associated Proteins in the Pathogenesis of Podocyte Injury , 2013, Current genomics.

[30]  C. Daniel,et al.  Podocytes are nonhematopoietic professional antigen-presenting cells. , 2013, Journal of the American Society of Nephrology : JASN.

[31]  M. Lanaspa,et al.  Toll-like receptor 3 ligand, polyIC, induces proteinuria and glomerular CD80, and increases urinary CD80 in mice. , 2013, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[32]  D. Gladman,et al.  Abatacept in the treatment of patients with psoriatic arthritis: results of a six-month, multicenter, randomized, double-blind, placebo-controlled, phase II trial. , 2011, Arthritis and rheumatism.

[33]  S. Bae,et al.  The efficacy and safety of abatacept in patients with non-life-threatening manifestations of systemic lupus erythematosus: results of a twelve-month, multicenter, exploratory, phase IIb, randomized, double-blind, placebo-controlled trial. , 2010, Arthritis and rheumatism.

[34]  C. Rivard,et al.  Urinary CD80 is elevated in minimal change disease but not in focal segmental glomerulosclerosis. , 2010, Kidney international.

[35]  Jai Radhakrishnan,et al.  Pathologic classification of diabetic nephropathy. , 2010, Journal of the American Society of Nephrology : JASN.

[36]  N. Baumgarth,et al.  B7-1/2 (CD80/CD86) Direct Signaling to B Cells Enhances IgG Secretion1 , 2009, The Journal of Immunology.

[37]  M. Segal,et al.  Urinary CD80 excretion increases in idiopathic minimal-change disease. , 2009, Journal of the American Society of Nephrology : JASN.

[38]  A. Kirk,et al.  A New Look at Blockade of T‐cell Costimulation: A Therapeutic Strategy for Long‐term Maintenance Immunosuppression , 2006, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[39]  F. Fallarino,et al.  Mechanisms of CTLA-4-Ig in tolerance induction. , 2006, Current pharmaceutical design.

[40]  Mary Collins,et al.  The B7 family of immune-regulatory ligands , 2005, Genome Biology.

[41]  P. Linsley,et al.  Rational Development of LEA29Y (belatacept), a High‐Affinity Variant of CTLA4‐Ig with Potent Immunosuppressive Properties , 2005, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[42]  R. Kalluri,et al.  Induction of B7-1 in podocytes is associated with nephrotic syndrome. , 2004, The Journal of clinical investigation.

[43]  Luc J. Smink,et al.  Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease , 2003, Nature.

[44]  Teven,et al.  EFFECTS OF LOSARTAN ON RENAL AND CARDIOVASCULAR OUTCOMES IN TYPE 2 DIABETES AND NEPHROPATHY EFFECTS OF LOSARTAN ON RENAL AND CARDIOVASCULAR OUTCOMES IN PATIENTS WITH TYPE 2 DIABETES AND NEPHROPATHY , 2001 .

[45]  D. Sansom,et al.  CD28, CTLA‐4 and their ligands: who does what and to whom? , 2000, Immunology.

[46]  A. Sharpe,et al.  Costimulation by B7-1 and B7-2 Is Required for Autoimmune Disease in MRL-Faslpr Mice1 , 2000, The Journal of Immunology.

[47]  N. Perico,et al.  Evidence that an angiotensin-converting enzyme inhibitor has a different effect on glomerular injury according to the different phase of the disease at which the treatment is started. , 1994, Journal of the American Society of Nephrology : JASN.

[48]  Wang Lm,et al.  A twelve month double-blind randomized study of the efficacy and immunogenicity of human and porcine insulins in non-insulin-dependent diabetics. , 1991 .

[49]  J. Cameron,et al.  Lupus Nephritis , 1959, Clinics in rheumatic diseases.